{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:58:18Z","timestamp":1773115098424,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejim.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T03:53:22Z","timestamp":1752724402000},"page":"106409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Baseline risk and outcome benefit from intensive blood pressure targeting. A systematic review"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4135-8936","authenticated-orcid":false,"given":"Paolo","family":"Verdecchia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-7985","authenticated-orcid":false,"given":"Fabio","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9877-0702","authenticated-orcid":false,"given":"Gianpaolo","family":"Reboldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejim.2025.07.005_bib0001","article-title":"Blood pressure targets in adults with hypertension: a clinical practice guideline from the AAFP","volume":"106","author":"Coles","year":"2022","journal-title":"Am Fam Physician"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.005_bib0002","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.005_bib0003","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.005_bib0004","first-page":"1","article-title":"Latin American Society of Hypertension guidelines on the management of arterial hypertension and related comorbidities in Latin America","volume":"43","author":"Sanchez","year":"2024","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.005_bib0006","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/HYPERTENSIONAHA.121.18192","article-title":"Hypertension pharmacological treatment in adults: a world health organization guideline executive summary","volume":"79","author":"Al-Makki","year":"2022","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.005_bib0007","first-page":"506","article-title":"Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children","volume":"34","author":"Nerenberg","year":"2018","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.005_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5694\/mja16.00526","article-title":"Guideline for the diagnosis and management of hypertension in adults - 2016","volume":"205","author":"Gabb","year":"2016","journal-title":"Med J Aust"},{"key":"10.1016\/j.ejim.2025.07.005_bib0009","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.005_bib0010","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2025.07.005_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.09.001","article-title":"The 2020 International Society of Hypertension global hypertension practice guidelines - key messages and clinical considerations","volume":"82","author":"Verdecchia","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.ejim.2025.07.005_bib0012","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"issue":"9118","key":"10.1016\/j.ejim.2025.07.005_bib0013","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.005_bib0014","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/ki.1995.361","article-title":"Strict\" blood pressure control and progression of renal disease in hypertensive nephrosclerosis","volume":"48","author":"Toto","year":"1995","journal-title":"Kidney Int"},{"issue":"7160","key":"10.1016\/j.ejim.2025.07.005_bib0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.005_bib0016","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/hr.2012.125","article-title":"Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure","volume":"35","author":"Asayama","year":"2012","journal-title":"Hypertens Res"},{"issue":"9891","key":"10.1016\/j.ejim.2025.07.005_bib0017","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","article-title":"Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial","volume":"382","author":"Study Group Metoki","year":"2013","journal-title":"Lancet"},{"issue":"9689","key":"10.1016\/j.ejim.2025.07.005_bib0018","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(09)61340-4","article-title":"Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial","volume":"374","author":"Verdecchia","year":"2009","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ejim.2025.07.005_bib0019","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ejim.2025.07.005_bib0020","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"issue":"9463","key":"10.1016\/j.ejim.2025.07.005_bib0021","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.005_bib0022","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/01.HYP.29.2.641","article-title":"Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group","volume":"29","author":"Lazarus","year":"1997","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.005_bib0023","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.146035","article-title":"Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study","volume":"56","author":"Ogihara","year":"2010","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.005_bib0024","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1291\/hypres.31.2115","article-title":"Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS)","volume":"31","year":"2008","journal-title":"Hypertens Res"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.005_bib0025","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaneurol.2019.2167","article-title":"Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis","volume":"76","author":"Kitagawa","year":"2019","journal-title":"JAMA Neurol"},{"issue":"10449","key":"10.1016\/j.ejim.2025.07.005_bib0026","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120 mmHg versus less than 140 mmHg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ejim.2025.07.005_bib0027","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.07.005_bib0028","article-title":"Intensive Blood-Pressure Control in Patients with Type 2 Diabetes","author":"Bi","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ejim.2025.07.005_bib0029","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.005_bib0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0895-4356(94)00098-B","article-title":"Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias?","volume":"48","author":"Gregoire","year":"1995","journal-title":"J Clin Epidemiol"},{"issue":"26","key":"10.1016\/j.ejim.2025.07.005_bib0031","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejim.2025.07.005_bib0032","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1001\/jama.287.21.2813","article-title":"Reporting number needed to treat and absolute risk reduction in randomized controlled trials","volume":"287","author":"Nuovo","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2025.07.005_bib0033","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2025.07.005_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073141","article-title":"Methods for deriving risk difference (absolute risk reduction) from a meta-analysis","volume":"381","author":"Murad","year":"2023","journal-title":"BMJ"},{"issue":"13","key":"10.1016\/j.ejim.2025.07.005_bib0035","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/1097-0258(20000715)19:13<1707::AID-SIM491>3.0.CO;2-P","article-title":"Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses","volume":"19","author":"Engels","year":"2000","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.ejim.2025.07.005_bib0036","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"N Engl J Med"},{"issue":"10380","key":"10.1016\/j.ejim.2025.07.005_bib0037","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0140-6736(22)02603-4","article-title":"Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial","volume":"401","author":"He","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.07.005_bib0038","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.ejim.2025.07.005_bib0039","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.005_bib0040","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jamia.1994.95153434","article-title":"Developing optimal search strategies for detecting clinically sound studies in MEDLINE","volume":"1","author":"Haynes","year":"1994","journal-title":"J Am Med Inform Assoc"},{"issue":"9237","key":"10.1016\/j.ejim.2025.07.005_bib0041","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(00)02786-0","article-title":"Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?","volume":"356","author":"McAuley","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.07.005_bib0042","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2025.07.005_bib0043","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.005_bib0044","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1161\/HYPERTENSIONAHA.124.23597","article-title":"Optimal antihypertensive systolic blood pressure: a systematic review and meta-analysis","volume":"81","author":"Whelton","year":"2024","journal-title":"Hypertension"},{"issue":"10022","key":"10.1016\/j.ejim.2025.07.005_bib0045","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.005_bib0046","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"issue":"7","key":"10.1016\/j.ejim.2025.07.005_bib0047","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/HJH.0b013e328338e2bb","article-title":"Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials","volume":"28","author":"Verdecchia","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2025.07.005_bib0048","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ejim.2025.07.005_bib0049","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","article-title":"Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis","volume":"2","author":"Bundy","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.005_bib0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"issue":"10285","key":"10.1016\/j.ejim.2025.07.005_bib0051","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"10305","key":"10.1016\/j.ejim.2025.07.005_bib0052","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","article-title":"Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis","volume":"398","year":"2021","journal-title":"Lancet"},{"issue":"10313","key":"10.1016\/j.ejim.2025.07.005_bib0053","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(21)01920-6","article-title":"Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis","volume":"398","author":"Nazarzadeh","year":"2021","journal-title":"Lancet"},{"issue":"10312","key":"10.1016\/j.ejim.2025.07.005_bib0054","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(21)01856-0","article-title":"Blood pressure treatment: how low should you go? - Authors' reply","volume":"398","author":"Rahimi","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejim.2025.07.005_bib0055","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/HJH.0b013e32832e9500","article-title":"Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?","volume":"27","author":"Zanchetti","year":"2009","journal-title":"J Hypertens"},{"issue":"17","key":"10.1016\/j.ejim.2025.07.005_bib0056","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1161\/CIRCULATIONAHA.116.025322","volume":"135","author":"Bress","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ejim.2025.07.005_bib0057","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/jamainternmed.2017.2924","article-title":"Injurious falls and syncope in older community-dwelling adults meeting inclusion criteria for SPRINT","volume":"177","author":"Sexton","year":"2017","journal-title":"JAMA Intern. Med."},{"issue":"6","key":"10.1016\/j.ejim.2025.07.005_bib0058","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M16-1754","article-title":"Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: a systematic review and meta-analysis","volume":"166","author":"Weiss","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2025.07.005_bib0059","article-title":"Systolic blood pressure targets below 120 mmHg are associated with reduced mortality: a meta-analysis","author":"Bergmann","year":"2025","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2025.07.005_bib0060","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.ejim.2025.07.005_bib0061","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2021.02.058","article-title":"Patient selection for intensive blood pressure management based on benefit and adverse events","volume":"77","author":"Bress","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.005_bib0062","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamacardio.2021.3187","article-title":"Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: findings from the SPRINT randomized clinical trial","volume":"6","author":"Berry","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"15","key":"10.1016\/j.ejim.2025.07.005_bib0063","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2018.01.074","article-title":"Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension","volume":"71","author":"Phillips","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.ejim.2025.07.005_bib0064","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1161\/CIRCULATIONAHA.113.002290","article-title":"Using benefit-based tailored treatment to improve the use of antihypertensive medications","volume":"128","author":"Sussman","year":"2013","journal-title":"Circulation"},{"issue":"9932","key":"10.1016\/j.ejim.2025.07.005_bib0065","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.ejim.2025.07.005_bib0066","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","article-title":"Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study","volume":"388","author":"Vidal-Petiot","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.005_bib0067","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/HYPERTENSIONAHA.114.04310","article-title":"Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease","volume":"65","author":"Verdecchia","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2025.07.005_bib0068","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejim.2024.01.025","article-title":"The lowest well tolerated blood pressure: a personalized target for all?","volume":"123","author":"Verdecchia","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2025.07.005_bib0069","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2023.07.034","article-title":"2023 ESH Guidelines. What are the main recommendations?","volume":"116","author":"Verdecchia","year":"2023","journal-title":"Eur J Intern Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525002778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525002778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:36:10Z","timestamp":1773070570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525002778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":68,"alternative-id":["S0953620525002778"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.07.005","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline risk and outcome benefit from intensive blood pressure targeting. A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106409"}}